KYTX vs. TECX, AUTL, TKNO, SNDL, TRDA, KMDA, MLYS, RNAC, ALT, and MREO
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Tectonic Therapeutic (TECX), Autolus Therapeutics (AUTL), Alpha Teknova (TKNO), SNDL (SNDL), Entrada Therapeutics (TRDA), Kamada (KMDA), Mineralys Therapeutics (MLYS), Cartesian Therapeutics (RNAC), Altimmune (ALT), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.
Kyverna Therapeutics vs.
Kyverna Therapeutics (NASDAQ:KYTX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
Kyverna Therapeutics received 2 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 66.67% of users gave Kyverna Therapeutics an outperform vote.
Kyverna Therapeutics presently has a consensus price target of $25.71, indicating a potential upside of 748.66%. Tectonic Therapeutic has a consensus price target of $80.50, indicating a potential upside of 126.31%. Given Kyverna Therapeutics' higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Tectonic Therapeutic.
18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Tectonic Therapeutic had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 6 mentions for Tectonic Therapeutic and 5 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.77 beat Tectonic Therapeutic's score of 0.70 indicating that Kyverna Therapeutics is being referred to more favorably in the media.
Tectonic Therapeutic has lower revenue, but higher earnings than Kyverna Therapeutics.
Tectonic Therapeutic's return on equity of -35.53% beat Kyverna Therapeutics' return on equity.
Summary
Tectonic Therapeutic beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Kyverna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYTX) was last updated on 2/17/2025 by MarketBeat.com Staff